Parainfluenza 3 Infections Early After Kidney or Simultaneous Pancreas–Kidney Transplantation

American Journal of Transplantation

Volumn 17, Issue 3, 2017, Pages 809-812

  Helantera I ^a   Anttila, V J ^a   Loginov, R ^a   Lempinen, M ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

clinical research practice; complication: infectious; infection and infectious agents; infectious disease; kidney transplantation nephrology; pancreas simultaneous pancreas kidney transplantation; viral

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; TACROLIMUS; VIRUS RNA;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DYSPNEA; EPIDEMIC; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; GRAFT RECIPIENT; HEART FAILURE; HUMAN; HUMAN PARAINFLUENZA VIRUS 3; HYPOXEMIA; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LUNG INFILTRATE; MULTIPLEX POLYMERASE CHAIN REACTION; PARAINFLUENZA VIRUS INFECTION; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RESPIRATORY VIRUS; VEIN THROMBOSIS; VIRUS SHEDDING; COMPLICATION; FEMALE; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; PARAMYXOVIRUS INFECTION; PATHOGENICITY; PROGNOSIS; RESPIRATORY TRACT INFECTION; RISK FACTOR; VIROLOGY;

FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; PARAINFLUENZA VIRUS 3, HUMAN; PARAMYXOVIRIDAE INFECTIONS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; RNA, VIRAL;

EID: 85007602660     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14146     Document Type: Article

References (20)

1. Vilchez RA, McCurry K, Dauber J, et al. The epidemiology of parainfluenza infection in lung transplant recipients. Clin Infect Dis 2001; 33: 2004–2008.
2. Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 2012; 119: 2738–2745.
3. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: Risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 573–578.
4. Vilchez RA, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza infection in adult lung transplant recipients: An emergent clinical syndrome with implications on allograft function. Am J Transplant 2003; 3: 116–120.
5. Seo S, Xie H, Campbell AP, et al. Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: Viral detection in the lung predicts outcome. Clin Infect Dis 2014; 58: 1357–1368.
6. Jokela P, Piiparinen H, Mannone L, Auvinen E, Lappalainen M. Performance of the Luminex xTAG Respiratory Viral Panel Fast in a clinical laboratory setting. J Virol Methods 2012; 182: 82–86.
7. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012; 307: 1941–1951.
8. Park SY, Sung H, Park KT, et al. Parainfluenza virus 3 pneumonia in a kidney transplant recipients. Transplant Infect Dis 2009; 11: 333–336.
9. DeFabritius AM, Riggio RR, David DS, Senterfit LB, Cheigh JS, Stenzel KH. Parainfluenza type 3 in a transplant unit. JAMA 1979; 241: 384–386.
10. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366.
11. Shah DP, Shah PK, Azzi JM, Chemaly RF. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. Cancer Lett 2016; 370: 358–364.
12. Ustun C, Slaby J, Shanley RM, et al. Human parainfluenza virus infection after hematopoietic stem cell transplantation: Risk factors, management, mortality, and changes over time. Biol Blood Marrow Transplant 2012; 18: 1580–1588.
13. Dignan F, Alvares C, Riley U, Ethell M, Cunningham D, Treleaven J, et al. Parainfluenza type 3 infection post stem cell transplant: High prevalence but low mortality. J Hosp Infect 2006; 63: 452–458.
14. Sridhar S, Luk HKH, Lau KP, Woo PCY. First report of severe parainfluenza virus 4B and rhinovirus C coinfection in a liver transplant recipient treated with immunoglobulin. J Clin Virol 2014; 61: 611–614.
15. Drozd DR, Limaye AP, Moss RB, et al. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transplant Infect Dis 2013; 15: E28–E32.
16. Guzman-Suarez BB, Buckely MW, Gilmoer ET, et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transplant Infect Dis 2012; 14: 427–433.
17. Hodson A, Kasliwal M, Streetly M, MacMahon E, Raj K. A parainfluenza-3 outbreak in a SCT unit: Sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality. Bone Marrow Transplant 2011; 46: 1545–1550.
18. Sydnor ERM, Greer A, Budd AP, et al. An outbreak of human parainfluenza virus 3 infection in an outpatient hematopoietic stem cell transplantation clinic. Am J Infect Contr 2012; 40: 601–605.
19. De Lima CRA, Mirandolli TB, Carneiro LC, et al. Prolonged respiratory viral shedding in transplant recipients. Transplant Infect Dis 2014; 16: 165–169.
20. Helanterä I, Anttila VJ, Lappalainen M, Lempinen M, Isoniemi H. Outbreak of influenza A(H1N1) in a kidney transplant unit—Protective effect of vaccination. Am J Transplant 2015; 15: 2470–2474.